Welcome to the Future of Eye Therapy with Clearside Biomedical
Breaking News: Fireside Chat at Stifel 2024 Healthcare Conference
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer and EVP, Head of Research & Development, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET in New York, NY.
Clearside Biomedical is at the forefront of innovation in delivering therapies to treat eye diseases through a groundbreaking method known as suprachoroidal space delivery. This unique approach allows for targeted and effective treatment of conditions that affect the back of the eye, such as macular degeneration and diabetic retinopathy.
The upcoming fireside chat at the Stifel 2024 Healthcare Conference presents an exciting opportunity for industry leaders and investors to learn more about Clearside Biomedical’s cutting-edge technology and the potential impact it could have on the future of eye healthcare.
George Lasezkay, PharmD, JD, and Victor Chong, M.D., MBA, will discuss the latest developments in Clearside’s research and development efforts, as well as the potential for their innovative therapies to revolutionize the way we treat eye diseases.
Stay tuned for more updates on Clearside Biomedical’s groundbreaking work in the field of eye therapy, as they continue to push the boundaries of what is possible in ocular medicine.
Impact on Individuals
As a potential patient, the advancements made by Clearside Biomedical could mean more effective treatments and better outcomes for those suffering from eye diseases. The ability to target therapies directly to the back of the eye could lead to fewer side effects and improved quality of life for individuals undergoing treatment.
Global Impact
On a global scale, Clearside Biomedical’s innovative approach to delivering therapies could have far-reaching implications for the field of ophthalmology. By improving the efficacy and precision of eye treatments, Clearside’s technology has the potential to make a significant impact on the way we approach and manage eye diseases worldwide.
Conclusion
Clearside Biomedical’s participation in the Stifel 2024 Healthcare Conference highlights the company’s commitment to advancing the field of eye therapy through groundbreaking research and development. As they continue to push the boundaries of what is possible in ocular medicine, the potential for improved treatments and better outcomes for patients around the world is truly exciting. Stay tuned for more updates on Clearside Biomedical’s revolutionary work in the realm of eye healthcare.
